Medicare Advantage Trends and Insights for U.S. Healthcare Payers
Medicare Advantage (MA) is rapidly transforming the healthcare landscape, making it an essential area of focus for healthcare Payers. With […]
Medicare
New CMS Guidelines for Part D Sponsors in 2025: What You Need to Know
The Centers for Medicare & Medicaid Services (CMS) recently announced changes to the Coordination of Benefits-Other Health Insurance (COB-OHI) file
Medicare Part C and D Reporting – Essential Updates for 2025
Every year, the Centers for Medicare & Medicaid Services (CMS) requires Medicare Advantage Organizations (MAOs) and Prescription Drug Plans (PDP)
How to Manage Prescription Drug Event (PDE) Data & Manufacturer Discount Program (MDP) in 2025
Two major provisions of the Inflation Reduction Act (IRA) that take effect in 2025 will require refresher training, even for
CMS 2026 Advance Notice: Key Updates, Payment Changes, and How to Submit Comments
To Usher in the new year, the Centers for Medicare & Medicaid Services (CMS) released a draft of the 2026
Key Updates in Medicare Parts C & D Appeals, Grievances, and Determinations Guidance
The Centers for Medicare & Medicaid Services (CMS) updated the Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals
CMS Reminder to Practice Vigilance Against Medicare Fraud, Waste and Abuse(FWA)
On April 15, 2022, the Centers for Medicare & Medicaid Services (CMS) released potential fraud, waste and abuse (FWA) trending
Medicare Prescription Payment Plan (M3P) Implementation: Key Considerations for Part D Plan Sponsors and PBMs
The upcoming Medicare Prescription Payment Plan (M3P), set to launch in January 2025, marks a significant shift in Medicare’s approach
Streamlining Medicare Advantage Organizations Member Communication: A Guide to CMS’s Model Materials for CY 2025
Every year, Medicare Advantage Organizations (MAO)1 must update their member communication materials, such as the Annual Notice of Change (ANOC),
Ensuring Accurate Drug Claims: Insights from CMS Audits and Best Practices
The Centers for Medicare & Medicaid Services (CMS) has added another category of drugs—immunosuppressants—to their national audits in collaboration with